Normalised quarter with impending margin pressure: ICICI Direct

ICICI Direct gives a preview on the earnings narrative for Q3FY22

Expect normal quarter in Q2FY22: Emkay

Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report

Steady quarter with margin improvement for Glenmark: ICICI Securities

India business grew 11.8% YoY vs mid-single digit industry growth.

Servier to acquire Edgewise muscular dystrophy business in $2.65 billion deal

The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments

AstraZeneca's India revenue climbs 33% YoY to Rs. 22.76 billion in FY26

While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications

Pfizer and Innovent Biologics strike $10 billion cancer drug deal

This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants

Pantherna acquisition to boost T-CURX’s clinical translation of non-viral In Vivo CAR-T strategies

Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier

AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia

The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,

Glenmark posts strong FY26 results with 27.5% revenue jump

Alkem Labs posts highest-ever EBITDA in FY26; Q4 revenue rises 14.6%

Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit